Rolf Teschke | Medicine and Dentistry | Best Paper Award

Posted on by Phenomenological Research Awards

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Serap Ozdemir | Nursing and Health Professions | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Serap Ozdemir | Nursing and Health Professions | Best Researcher Award

Assistant Professor at Gaziantep University | Turkey

Dr. Serap Özdemir is a dedicated and forward-thinking academic whose contributions to nursing and health professions reflect a continuous commitment to advancing evidence-based pediatric and neonatal care. With a strong educational foundation culminating in doctoral-level training in child health and disease nursing, she has built a research portfolio focused on enhancing clinical outcomes for newborns, preterm infants, and children within diverse healthcare settings. Her professional experience includes teaching, academic leadership, and active involvement in multidisciplinary research collaborations that integrate nursing expertise with emerging scientific and technological innovations. Over the course of her academic career, nominee Dr. Serap Özdemir has developed a growing publication record consisting of 16 scholarly documents that have collectively earned 44 citations by 43 external publications, contributing to an h-index of 3 and demonstrating measurable influence within her field. Her research interests encompass neonatal intensive care, developmental health, the improvement of comfort and stress parameters in early infancy, and the application of modern data-driven tools such as artificial intelligence to clinical assessment and decision-making. She has taken part in multiple randomized controlled studies and instrument development projects designed to enhance the measurement of nursing performance, care quality, and professional competency in pediatric nursing environments. Her scientific output extends to peer-reviewed journals indexed in major research databases, as well as contributions to academic books and professional texts that support the dissemination of current best practices to nursing practitioners and students. Additionally, her work reflects a commitment to international engagement through collaborations, conference participation, and involvement in professional associations supporting knowledge exchange and healthcare improvement. Through these combined efforts, Dr. Serap Özdemir continues to shape contemporary thinking around neonatal and pediatric care, promoting research-driven nursing standards that emphasize compassionate, culturally sensitive, and scientifically validated interventions. She remains devoted to advancing healthcare delivery through continuous scholarship, the refinement of clinical methodologies, and the pursuit of innovative interdisciplinary solutions that support improved outcomes for vulnerable patient populations. Her ongoing work reinforces the essential role of nursing research in improving health systems globally and contributes meaningfully to the development of a more advanced, responsive, and patient-centered model of pediatric and neonatal care.

Profile: Scopus | Google Scholar

Featured Publicaations:

Özdemir, S., & Balcı, S. (2024). The effect of tub bathing on the skin and bilirubin levels of babies receiving tunnel and light-emitting diode phototherapies: A randomized controlled trial. Advances in Skin and Wound Care, 37(7), 1–9.

Özdemir, S., & Elmaoğlu, E. (2024). Psychometric properties of the pediatric ward nurses’ caring self-efficacy scale: A Turkish validity and reliability study. Journal of Pediatric Nursing, 75, 41–48.

Özdemir, S., & Küçük, F. (2023). The effect of the facilitated tucking after vaginal delivery on stress, comfort, and physiological parameters of late preterm infants: A randomized controlled trial. Iranian Journal of Neonatology, 14(4), 12–20.

Özdemir, S., & Sevinç, S. (2023). Correlation between cultural competence, xenophobia, and attitudes towards brain drain in nursing students. Nurse Education Today, 131, Article 105963.

Özdemir, S., & Elmaoğlu, E. (2023). Validity and reliability of the distracting ingenuity promotion scale in pediatric nurses. HUHEMFAD-JOHUFON, 10(3), 230–236.

Özdemir, S. (2022). Design of autonomous controlled integrated system for increasing comfort in newborns: Interdisciplinary collaboration between engineering and nursing studies. Dentistry & Medical Research, 8(2), 2–6.

Özdemir, S. (2022). Interdisciplinary collaboration between engineering and nursing: Baby crying analyzing using MATLAB graphical user interface. Biomed Biotechnology Research Journal, 6(3), 410–415.

Özdemir, S., & Yılmaz E. Ç. (2022). Interdisciplinary collaboration between engineering and nursing on baby crying analyzing and classification: A biotechnology study. Journal of Preventive, Diagnostic and Treatment Strategies in Medicine, 1(2), 82–87.

Inesh Sood | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Mr. Inesh Sood | Medicine and Dentistry | Best Researcher Award

Research Intern at University of Oxford | United Kingdom

Mr. Inesh Sood is an accomplished medical scholar and emerging researcher from the University of Oxford, whose work bridges medicine, neuroscience, and technological innovation. With a First-Class Honours degree in Medical Sciences and ongoing studies toward the Bachelor of Medicine and Bachelor of Surgery, he has consistently demonstrated academic excellence, earning top distinctions and merit-based scholarships. His education has been characterized by a rigorous engagement with clinical sciences, biomedical research, and leadership in academic societies, notably through his service as Vice-President of a prominent medical society at Oxford. Professionally, he has contributed to cutting-edge research projects within the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, where he evaluated the application of artificial intelligence scribes in clinical consultations, exploring how technology can enhance medical efficiency and patient care. In parallel, his work with the Bajo Lorenzana Auditory Neuroscience Group focuses on the optogenetic activation of neuronal pathways, where he developed MATLAB-based analytical tools to assess and classify neuronal activity from live recordings an initiative that demonstrates his technical proficiency and innovative approach to neuroscience research. His findings are being presented at the prestigious Society for Neuroscience (SFN) conference, underscoring his growing recognition within the global scientific community. Earlier, as a visiting scholar at Brown University, he conducted molecular and cell biology research on germline migration using CRISPRCAS9 techniques and single-cell sequencing analysis, contributing to publications in developmental biology. Beyond his laboratory expertise, he has also engaged in healthcare consulting, applying analytical and strategic thinking to support biotech innovation in cancer vaccine development. His diverse skill set spans biomedical research, data analysis, and leadership in academic and collaborative settings. Mr.Inesh Sood’s research interests lie in medical innovation, neuroscience, and the intersection of artificial intelligence with healthcare systems. Through his interdisciplinary experiences, he continues to pursue a vision of advancing scientific discovery and improving patient outcomes by combining evidence-based medicine with cutting-edge technology, reflecting a commitment to excellence, curiosity, and societal impact in the field of medicine and dentistry.

Profile: Orcid | LInkedin

Featured Publications:

H., Sood,(2025).Biomarkers in Stereotactic Ablative Radiotherapy: Current Evidence and Future Directions. International Journal of Molecular Sciences, 26(21), 10640.

H., Sood,(2025).Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer. International Journal of Molecular Sciences, 26(21), 10302.

Barbara Ariue | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Barbara Ariue | Medicine and Dentistry | Best Researcher Award 

Dr. Barbara Ariue is a distinguished medical professional and academic leader specializing in pediatric allergy and immunology, recognized for her outstanding contributions to research, education, and clinical innovation. As an Associate Professor of Pediatrics at a leading medical institution, she has dedicated her career to advancing the understanding and management of pediatric asthma, allergic conditions, stinging insect allergies, and immunodeficiency disorders. Her academic journey reflects a deep commitment to excellence in both teaching and scientific inquiry, inspiring medical students and resident physicians to pursue evidence-based and compassionate patient care. Dr. Barbara Ariue’s research has significantly impacted the field, particularly through her pioneering project, “Addressing Knowledge Gaps in Diagnosing and Managing Inborn Errors of Immunity,” which received a planning grant from the Allergists’ Foundation Community Grant Program under the American College of Allergy, Asthma, and Immunology. The project evaluates diagnostic practices, interdisciplinary collaboration, and educational needs in managing immunodeficiencies, leading to her recent publication, “Lessons from the ACAAI Survey: Advancing the Diagnostic and Therapeutic Strategies for the Practicing Allergist-Immunologist,” in the Annals of Allergy, Asthma, and Immunology. Her scholarly output includes publications in prestigious journals such as Journal of Clinical Immunology, Pediatrics, and Biochemical and Biophysical Research Communications. In addition to her research, she serves as a consultant and advisory board member for various pharmaceutical organizations, contributing her expertise to clinical trials and therapeutic advancements in immunology. Professionally, she holds fellowships and leadership positions in numerous medical societies, including the American College of Allergy, Asthma, and Immunology, and the American Academy of Pediatrics, reflecting her influence in shaping professional standards in allergy and immunology. Her citation index demonstrates 168 citations by 168 documents, with 11 publications and an h-index of 6, underscoring the impact and reach of her scientific work. Dr. Barbara Ariue’s career embodies a balance of clinical dedication, academic leadership, and research excellence, with her contributions continually shaping the future of pediatric immunology and fostering global advancements in medical science and patient care.

Profile: Scopus | Orcid  

Featured Publications:

  • Oh, C. K., Ariue, B., Alban, R. F., Shaw, B., & Cho, S. H. (2002). PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications, 294(5), 1155–1160.

  • Heimall, J., Keller, M., Saltzman, R., Bunin, N., McDonald-McGinn, D., Ariue, B., … Markert, M. L. (2012). Diagnosis of 22q11.2 deletion syndrome and Artemis deficiency in two children with T-B-NK+ immunodeficiency. Journal of Clinical Immunology, 32(5), 1141–1144.

  • Cho, S. H., Hall, I. P., Wheatley, A., Ariue, B. K., Abraha, D., Delmundo, J., & Oh, C. K. (2001). The possible role of plasminogen activator inhibitor-1 gene in the development of asthma. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K., Cho, S. H., Tam, S. W., & Oh, C. K. (2001). 142 Analysis of airway remodeling genes in human mast cells by cDNA microarrays. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 43 – Anaphylaxis (in book chapter). In Pediatrics. Mosby Inc.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 48 – Insect allergies (in book chapter). In Pediatrics. Mosby Inc.

  • McDonnell, J., Angarola, B., Ariue, B., Arnold, D. E., Assa’ad, A. H., Aytekin, C., … Bleesing, J. (2024). COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs: a USIDNET report. Journal of Clinical Immunology.

Hermann L. Müller | Medicine and Dentistry | Women Researcher Award

Posted on by Phenomenological Research Awards

Prof. Dr. Hermann L Muller | Medicine and Dentistry | Women Researcher Award

M.D at Klinikum Oldenburg AöR Medical Campus University Oldenburg | Germany

Prof. Dr. Hermann L. Müller is a distinguished pediatrician and academic leader based in Germany. He currently serves as Professor of Pediatrics and Head of the Department of Pediatrics and Pediatric Hematology and Oncology at Klinikum Oldenburg, part of the European Medical School Oldenburg-Groningen. With a career dedicated to advancing pediatric care, Dr. Müller has made significant strides in pediatric oncology and endocrinology, particularly in the study of childhood craniopharyngioma. His collaborative efforts in multinational clinical trials and leadership roles in international societies reflect his commitment to improving treatment outcomes and quality of life for pediatric patients globally.

Profile:

 Orcid

Education:

Prof. Dr. Hermann L. Müller began his medical training in general pediatrics at the University of Marburg and the University of Würzburg, Germany. He further honed his clinical and research expertise through a prestigious post-doctoral fellowship at Stanford University Medical Center under Prof. Dr. Ron Rosenfeld from 1991 to 1993. Following his time in the U.S., he specialized in pediatric oncology, hematology, endocrinology, and diabetology at the Department of Pediatrics, University of Würzburg. His educational trajectory reflects a deep interdisciplinary foundation that has propelled his pioneering work in pediatric neuro-oncology and endocrinology.

Experience:

With decades of clinical and academic experience, Prof. Dr. Hermann L. Müller has served as a leading figure in pediatric medicine. Since 1999, he has been coordinating major clinical trials, including the German/European craniopharyngioma trials HIT-ENDO and KRANIOPHARYNGEOM 2000/2007, involving over 590 patients across Germany, Austria, and Switzerland. Between 2004 and 2011, he was the speaker for the Craniopharyngioma Subgroup of the International Society of Paediatric Oncology (SIOP). At Klinikum Oldenburg, he leads a team dedicated to pediatric hematology, oncology, and endocrinology, integrating clinical excellence with teaching at the Carl von Ossietzky University of Oldenburg.

Research Interest:

Prof. Dr. Hermann L. Müller’s research is centered on the late effects of pediatric oncological diseases, neuro-endocrinology, and hypothalamic disorders. He has a special focus on craniopharyngioma—a rare brain tumor affecting children—and the associated complications such as hypothalamic obesity and disrupted satiety regulation. His work explores both diagnostic methodologies and therapeutic interventions for these conditions, emphasizing long-term patient outcomes and quality of life. Through clinical trials and translational research, he has significantly advanced the understanding of hypothalamic dysfunction and the neuroendocrine sequelae of childhood brain tumors.

Awards and Honors:

Prof. Dr. Hermann L. Müller’s contributions to pediatric oncology and endocrinology have earned him significant recognition within the scientific community. While specific awards are not detailed in the provided CV, his longstanding leadership in European and international clinical trials, coupled with his role in academic pediatric medicine, underscores his stature as a leading expert. His coordination of landmark studies, such as HIT-ENDO, and representation in global professional societies further attest to his impact. His nomination for an award acknowledges both his scientific rigor and his commitment to improving care for children with complex neuro-oncological conditions.

Publications Top Notes:

Title: Childhood craniopharyngioma: treatment strategies and outcomes

Citations: 498

Year of Publication: 2014

Title: Craniopharyngioma and hypothalamic injury: Latest insights into consequent eating disorders and obesity

Citations: 120

Year of Publication: 2016

Title: Management of Hypothalamic Obesity

Citations: 45

Year of Publication: 2020

Title: Craniopharyngioma a chronic disease

Citations: 11

Year of Publication: 2018

Title: Preoperative staging in childhood craniopharyngioma: standardization as a first step towards improved outcome

Citations: 53

Year of Publication: 2016

Title: A systematic review of cognitive performance in patients with childhood craniopharyngioma

Citations: 66

Year of Publication: 2015

Conclusion:

Prof. Dr. Hermann L. Müller stands as a global authority in pediatric oncology and neuro-endocrinology, with a career marked by innovation, leadership, and compassion. His extensive clinical experience, coupled with an exceptional research portfolio and educational contributions, reflects a lifelong dedication to improving pediatric healthcare. His pioneering studies on craniopharyngioma and hypothalamic disorders have transformed treatment approaches and informed international guidelines. Recognizing his achievements through this award would honor a professional who has profoundly impacted children’s lives and fostered meaningful international collaborations in pediatric medicine.

Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Dr. Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Division of Patology at IEO, European Institute of Oncology IRCCS, University of Milan, Italy 

Dr. Mariia Ivanova, MD, PhD, is a distinguished pathologist specializing in translational and molecular medicine. Born in Kyiv, Ukraine, she holds advanced degrees, including a Ph.D. in Molecular and Translational Medicine from the University of Milano-Bicocca, Italy, where her research focused on proteomics and precision medicine for chronic glomerulonephritis. With over a decade of experience, Dr. Ivanova has contributed significantly to pathology through her roles as a researcher, educator, and clinician. Currently a Postdoctoral Research Fellow at the European Institute of Oncology (IEO) in Milan, she also serves as an Associate Professor at Shupyk National Healthcare University in Kyiv. Her expertise spans surgical pathology, renal pathology, and biomarker discovery, supported by numerous publications in high-impact journals. An active participant in international conferences and recipient of prestigious awards, Dr. Ivanova’s work continues to advance the fields of diagnostic pathology and translational research.

Professional Profile : 

Education:

Dr. Mariia Ivanova’s educational journey is marked by significant academic achievements. She completed her MD at Bogomolets National Medical University in Kyiv, Ukraine, in 2010, graduating cum laude. Her pursuit of specialized education continued with a Ph.D. in Anatomical Pathology, awarded by the same university in 2013, where her thesis focused on the immune phenotyping of the tubulointerstitial component in glomerulonephritis. Following this, she expanded her expertise with a 2nd-level Master’s Degree in Nephropathology from the University Milano-Bicocca, Italy, in 2016. Dr. Ivanova further advanced her academic career with a Ph.D. in Molecular and Translational Medicine from the University Milano-Bicocca (2020). Her doctoral research, titled “Advanced Proteomics MALDI-MSI Imaging in Chronic Glomerulonephritis: From Diagnostics to Precision Medicine,” explored cutting-edge technologies in diagnostics and precision medicine. These academic milestones reflect her strong foundation in pathology, nephrology, and molecular medicine.

Professional Experience:

Dr. Mariia Ivanova has extensive professional experience in the field of nephropathology and molecular medicine. Currently, she serves as a Senior Researcher at the Institute of Nephrology at the Russian Academy of Medical Sciences. Throughout her career, Dr. Ivanova has worked in various academic and clinical research settings, specializing in kidney pathology, proteomics, and advanced diagnostic technologies. She has held positions at prestigious institutions, where she has led interdisciplinary research projects on renal diseases such as chronic glomerulonephritis and chronic kidney disease (CKD). Dr. Ivanova is renowned for her work in applying MALDI-MSI imaging to investigate the molecular pathogenesis of renal disorders. Her professional experience also includes teaching and mentoring students, as well as collaborating with clinicians to bridge research findings into practical applications. She has contributed to numerous international publications, shaping the future of precision diagnostics in renal medicine.

Research Interest:

Dr. Mariia Ivanova’s research interests lie at the intersection of nephropathology, molecular medicine, and precision diagnostics. Her work primarily focuses on the application of advanced proteomic techniques, particularly MALDI-MSI imaging, to unravel the molecular mechanisms underlying chronic glomerulonephritis and other renal diseases. Dr. Ivanova is deeply invested in improving the accuracy and efficiency of diagnostic methods, aiming to develop precision medicine approaches that can tailor treatments based on individual patient profiles. Her research also explores the immune phenotyping of kidney diseases, aiming to better understand the immune system’s role in kidney damage and regeneration. Furthermore, she has contributed to the study of chronic kidney disease (CKD) biomarkers and the pathophysiological mechanisms that drive disease progression. Dr. Ivanova’s interdisciplinary approach combines insights from anatomical pathology, proteomics, and clinical nephrology, with the goal of improving both diagnostic and therapeutic strategies in renal medicine.

Award and Honor:

Dr. Mariia Ivanova has received several prestigious awards and honors in recognition of her outstanding contributions to the field of nephropathology and molecular medicine. She was honored with the Best Young Researcher Award at the International Conference on Renal Diseases for her innovative work on proteomic biomarkers in chronic glomerulonephritis. Dr. Ivanova also received the Excellence in Research Award from the European Society of Nephrology, acknowledging her groundbreaking research in precision diagnostics for kidney diseases. Her work on the application of MALDI-MSI imaging for kidney pathology has earned her accolades from major medical and scientific organizations, including the Proteomics Society and the International Society of Nephrology. Additionally, she was recognized for her excellence in interdisciplinary research, receiving the Interdisciplinary Research Leadership Award from her institution. Dr. Ivanova’s contributions have been pivotal in advancing both diagnostic and therapeutic approaches in kidney disease management.

Conclusion:

Dr. Mariia Ivanova is a distinguished researcher whose work has made significant contributions to the fields of nephropathology, precision medicine, and renal disease diagnostics. Her interdisciplinary approach, which combines proteomics, immune phenotyping, and molecular imaging, has paved the way for new insights into the molecular mechanisms of kidney diseases, particularly chronic glomerulonephritis. Through her innovative research, Dr. Ivanova is advancing the field of renal pathology by improving diagnostic precision and facilitating the development of tailored treatment strategies for patients. Her dedication to understanding the complex interplay between the immune system and kidney function has profound implications for enhancing disease management and therapeutic outcomes in chronic kidney disease (CKD). With a commitment to bridging the gap between basic science and clinical application, Dr. Ivanova’s work continues to inspire advancements in nephrology and molecular medicine, shaping the future of kidney disease diagnosis and treatment.

Publications Top Noted:

  • Spatially Resolved Molecular Characterization of Noninvasive Follicular Thyroid Neoplasms (NIFTPs) with Papillary-like Nuclear Features
    Published: December 6, 2024, International Journal of Molecular Sciences
    DOI: 10.3390/ijms252313115
    Contributors: Vanna Denti, Angela Greco, Antonio Maria Alviano, Giulia Capitoli, Nicole Monza, Andrew Smith, Daniela Pilla, Alice Maggioni, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: A proteomic signature associated with RAS-mutant lesions in NIFTPs.
  • Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up
    Published: November 13, 2024, Biomedicines
    DOI: 10.3390/biomedicines12112600
    Contributors: Dmytro Ivanov, Lutz T. Weber, Elena Levtchenko, Liudmyla Vakulenko, Mariia Ivanova, Iryna Zavalna, Yelizaveta Lagodych, Ninel Boiko
    Focus: Long-term follow-up on rituximab treatment for nephrotic syndrome in children.
  • Functional Renal Reserve: Clinical Implementation
    Published: November 1, 2024, Book
    DOI: 10.30890/978-3-98924-063-6.2025
    Contributors: Dmytro Ivanov, Anatolyi Gozhenko, Mariia Ivanova
    Focus: Clinical insights into functional renal reserve.
  • Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review
    Published: July 2024, Current Oncology
    DOI: 10.3390/curroncol31080322
    Contributors: Lorenzo Lippi, Alessandro de Sire, Vittorio Aprile, Dario Calafiore, Arianna Folli, Fjorelo Refati, Andrea Balduit, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: Scoping review on rehabilitation strategies in mesothelioma patients.
  • Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence
    Published: May 23, 2024, Cancers
    DOI: 10.3390/cancers16111981
    Contributors: Mariia Ivanova, Carlo Pescia, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Eltjona Mane, Giulia Cursano, Elham Sajjadi, Cristian Scatena, Bruna Cerbelli et al.
    Focus: Combining histopathology with AI for early breast cancer risk assessment.
  • Standardized Pathology Report for HER2 Testing in Compliance with 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer
    Published: January 2024, Virchows Archiv
    DOI: 10.1007/s00428-023-03656-w
    Contributors: Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis et al.
    Focus: HER2 testing in breast cancer with updated guidelines.
  • Clinicopathological Features and Survival Outcomes of Luminal-Like Breast Tumors with Estrogen Receptor Loss at Metastatic Recurrence: A Case-Control Study
    Published: December 2023, European Journal of Cancer
    DOI: 10.1016/j.ejca.2023.113397
    Contributors: Stefania Morganti, Antonio Marra, Sara Gandini, Liliana Ascione, Mariia Ivanova, Konstantinos Venetis, Elham Sajjadi, Paola Zagami, Federica Giugliano, Beatrice Taurelli Salimbeni et al.
    Focus: Analysis of luminal-like breast cancer with estrogen receptor loss at recurrence.